FGF23 and endothelial dysfunction: Novel candidates such as fibroblast growth factor-23 (FGF-23), soluble urokinase plasminogen activator receptor (suPAR), and Klotho have been linked to disease progression, endothelial dysfunction, and cardiovascular events [10,11].